Bimagrumab 3rd Novartis drug to win FDA 'breakthrough' designation

21 Aug 2013

• By Donna Young

Novartis has won its third breakthrough therapy designation from the US FDA, which granted the status to the Swiss drug maker's investigational muscle-wasting disease drug bimagrumab (BYM338), a fully human monoclonal antibody.

Shares of Novartis jumped 3%, or $2

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Strong Showing For Bayer’s Pharma Business In Uncertain Times

13 May 2025

• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

08 May 2025

• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Copycats Compound Novo’s Wegovy Growth Problems

07 May 2025

• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Merck & Co. CMO Eliav Barr Assures On Pipeline As Keytruda LOE Looms Large

28 Apr 2025

• By Jessica Merrill

Chief medical officer Eliav Barr, responsible for overseeing clinical development, talked to Scrip in an interview at Merck’s headquarters about the company’s pipeline diversification.